Plasma orosomucoid 2 as a potential risk marker of cholangiocarcinoma

Abstract

BACKGROUND:

Cholangiocarcinoma (CCA), a malignant tumor of the biliary epithelium, is a tumor with an ineffective diagnosis and poor prognosis. We have previously identified an overexpression of orosomucoid 2(ORM2) along with CCA development in hamsters using a proteomics technique.

OBJECTIVE:

To evaluate plasma ORM2 as a candidate risk biomarker for CCA in humans.

METHODS:

Overexpression of ORM2 in CCA patients was assessed by western blotting and immunohistochemistry. The diagnostic efficacy of ORM2 was investigated in the plasma of patients with hepatobiliary diseases - including 46 cholangitis patients and 70 CCA patients - compared with 20 healthy individuals, using enzyme-linked immunosorbent assay (ELISA).

RESULTS:

Overexpression of ORM2 was observed in the cytoplasm of bile duct tumor cells and in the adjacent normal hepatocytes at a much higher intensity than in normal bile duct cells. Western blot analysis revealed that its expression was significantly higher in the plasma of CCA patients compared with that of healthy individuals (P < 0.01). ELISA showed that plasma ORM2 levels were significantly elevated in CCA and cholangitis groups compared with healthy individuals (P < 0.0001). The sensitivity and specificity of ORM2 in distinguishing CCA patients from healthy patients were 92.86% and 73.68%, respectively.

CONCLUSIONS:

Plasma ORM2 could serve as a new risk marker for CCA.

Keywords

Biomarker cholangiocarcinoma cholangitis hepatobiliary disease orosomucoid 2 ELISA

References

Shin

H.R.

, Oh

J.K.

, Masuyer

, Curado

M.P.

, Bouvard

, Fang

Y.Y.

, Wiangnon

, Sripa

and Hong

S.T.

, Epidemiology of cholangiocarcinoma: An update focusing on risk factors, Cancer Sci 101 (2010), 579-585.

Sripa

and Pairojkul

, Cholangiocarcinoma: lessons from Thailand, Curr Opin Gastroenterol 24 (2008), 349-356.

Bonney

G.K.

, Craven

R.A.

, Prasad

, Melcher

A.F.

, Selby

P.J.

and Banks

R.E.

, Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol 9 (2008), 149-158.

Patel

, Cholangiocarcinoma-controversies and challenges, Nat Rev Gastroenterol Hepatol 8 (2011), 189-200.

Pattanathien

, Khuntikeo

, Promthet

and Kamsa-Ard

, Survival rate of extrahepatic cholangiocarcinoma patients after surgical treatment in Thailand, Asian Pac J Cancer Prev 14 (2013), 321-324.

Sriputtha

, Khuntikeo

, Promthet

and Kamsa-Ard

, Survival rate of intrahepatic cholangiocarcinoma patients after surgical treatment in Thailand, Asian Pac J Cancer Prev 14 (2013), 1107-1110.

Qin

X.L.

, Wang

Z.R.

, Shi

J.S.

, Lu

, Wang

and He

Q.R.

, Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA, World J Gastroenterol 10 (2004), 427-432.

Srinivas

P.R.

, Verma

, Zhao

and Srivastava

, Proteomics for cancer biomarker discovery, Clin Chem 48 (2002), 1160-1169.

Rucksaken

, Khoontawad

, Roytrakul

, Pinlaor

, Hiraku

, Wongkham

, Pairojkul

, Boonmars

and Pinlaor

, Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma, Cancer Biomark 12 (2012), 81-95.

10.

Ceciliani

and Pocacqua

, The acute phase protein alpha1-acid glycoprotein: A model for altered glycosylation during diseases, Curr Protein Pept Sci 8 (2007), 91-108.

11.

Baumann

and Gauldie

, Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation, Mol Biol Med 7 (1990), 147-159.

12.

Zhang

, Xiao

, Liu

, Du

, Wang

, Zheng

, Li

, Dong

, Zhuang

and Wang

, The potential role of ORM2 in the development of colorectal cancer, PLoS One 7 (2012), e31868.

13.

Bachtiar

, Santoso

J.M.

, Atmanegara

, Gani

R.A.

, Hasan

, Lesmana

L.A.

, Sulaiman

, Gu

and Tai

, Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma, Clin Chim Acta 399 (2009), 97-101.

14.

Yongvanit

, Pinlaor

and Bartsch

, Oxidative and nitrative DNA damage: key events in opisthorchiasis-induced carcinogenesis, Parasitol Int 61 (2012), 130-135.

15.

DeOliveira

M.L.

, Cunningham

S.C.

, Cameron

J.L.

, Kamangar

, Winter

J.M.

, Lillemoe

K.D.

, Choti

M.A.

, Yeo

C.J.

and Schulick

R.D.

, Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution, Ann Surg 245 (2007), 755-762.

16.

Lazaridis

K.N.

and Gores

G.J.

, Primary sclerosing cholangitis and cholangiocarcinoma, Semin Liver Dis 26 (2006), 42-51.

17.

Bjornsson

, Kilander

and Olsson

, CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis, Liver 19 (1999), 501-508.

18.

Ehlken

and Schramm

, Primary sclerosing cholangitis and cholangiocarcinoma: pathogenesis and modes of diagnostics, Dig Dis 31 (2013), 118-125.

19.

Sinakos

, Saenger

A.K.

, Keach

, Kim

W.R.

and Lindor

K.D.

, Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma, Clin Gastroenterol Hepatol 9 (2011), 434-439 e431.

20.

Tyson

G.L.

and El-Serag

H.B.

, Risk factors for cholangiocarcinoma, Hepatology 54 (2011), 173-184.

21.

Fournier

, Medjoubi

N.N.

and Porquet

, Alpha-1-acid glycoprotein, Biochim Biophys Acta 1482 (2000), 157-171.

22.

Ozeki

, Imanishi

, Uchiyama

, Sanefuji

, Fujiwara

, Mizuno

, Tanaka

and Suzuki

, Alpha 1-acid glycoprotein and hepatic fibrosis, Br J Exp Pathol 69 (1988), 589-595.

23.

Magid

, Guldager

, Hesse

and Christiansen

M.S.

, Monitoring urinary orosomucoid in acute inflammation: observations on urinary excretion of orosomucoid, albumin, alpha1-microglobulin, and IgG, Clin Chem 51 (2005), 2052-2058.

24.

Tsutsumi

and Takase

, Usefulness of microheterogeneity of serum alpha 1-acidglycoprotein as a marker for alcohol abuse, Alcohol 25 (2001), 181-184.

25.

Van Den Heuvel

M.M.

, Poland

D.C.

, De Graaff

C.S.

, Hoefsmit

E.C.

, Postmus

P.E.

, Beelen

R.H.

and Van Dijk

, The degree of branching of the glycans of alpha(1)-acid glycoprotein in asthma. A correlation with lung function and inflammatory parameters, Am J Respir Crit Care Med 161 (2000), 1972-1978.

26.

Romao Jr.

J.E.

, Haiashi

A.R.

, Elias

R.M.

, Luders

, Ferraboli

, Castro

M.C.

and Abensur

, Positive acute-phase inflammatory markers in different stages of chronic kidney disease, Am J Nephrol 26 (2006), 59-66.

27.

Irmak

, Tilki

, Heukeshoven

, Oliveira-Ferrer

, Friedrich

, Huland

and Ergun

, Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer, Proteomics 5 (2005), 4296-4304.

28.

Ochi

, Studies on immunological characteristic of CEA-CEA may be a biosynthetic precursor of alpha 1-acid glycoprotein-, Gan To Kagaku Ryoho 10 (1983), 585-594.

29.

Ochi

, Fujiyama

, Hosoda

, Miyazaki

, Yoshimura

, Hachiya

and Kajita

, Immunological similarity of CEA with alpha 1-acid glycoprotein (orosomucoid), Clin Chim Acta 122 (1982), 145-160.

30.

Dube

J.Y.

, Paradis

, Tetu

and Tremblay

R.R.

, Synthesis of alpha 1-acid glycoprotein by the human prostate, Prostate 15 (1989), 251-258.

31.

R.C.

, Roberts

A.N.

, Wilson

R.G.

, Latner

A.L.

and Turner

G.A.

, Analyses of protein extracts of human breast cancers: changes in glycoprotein content linked to the malignant phenotype, Br J Cancer 55 (1987), 249-254.

32.

Yamamoto

, Takasaki

, Yoshikawa

, Ueno

and Nakano

, Does gross appearance indicate prognosis in intrahepatic cholangiocarcinoma? J Surg Oncol 69 (1998), 162-167.

33.

Guglielmi

, Ruzzenente

, Campagnaro

, Pachera

, Valdegamberi

, Nicoli

, Cappellani

, Malfermoni

and Iacono

, Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection, World J Surg 33 (2009), 1247-1254.